Brought to you by 
Australian drug discovery company AdAlta raises $A10mm in IPO on ASX
20 Sep 2017
Executive Summary
AdAlta Ltd. (biotech specializing in the discovery of protein therapeutics) grossed $A10mm ($7.6mm) in an over-subscribed IPO on the ASX of 40mm new shares at $A0.25.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Australian drug discovery company AdAlta raises $A10mm in IPO on ASX
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice